Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Cash (2020 - 2025)

RxSight (RXST) has disclosed Change in Cash for 6 consecutive years, with -$9.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 40445.83% year-over-year to -$9.7 million, compared with a TTM value of $3.2 million through Dec 2025, down 54.02%, and an annual FY2025 reading of $3.2 million, down 54.02% over the prior year.
  • Change in Cash was -$9.7 million for Q4 2025 at RxSight, up from -$10.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $26.5 million in Q3 2021 and bottomed at -$43.7 million in Q4 2021.
  • Average Change in Cash over 5 years is $312200.0, with a median of -$147000.0 recorded in 2022.
  • The sharpest move saw Change in Cash soared 5409.4% in 2021, then tumbled 40445.83% in 2025.
  • Year by year, Change in Cash stood at -$43.7 million in 2021, then skyrocketed by 106.58% to $2.9 million in 2022, then crashed by 105.78% to -$166000.0 in 2023, then skyrocketed by 114.46% to $24000.0 in 2024, then crashed by 40445.83% to -$9.7 million in 2025.
  • Business Quant data shows Change in Cash for RXST at -$9.7 million in Q4 2025, -$10.7 million in Q3 2025, and $12.4 million in Q2 2025.